Equities

Brooks Laboratories Ltd

BROOKS:NSI

Brooks Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)139.66
  • Today's Change-2.82 / -1.98%
  • Shares traded4.75k
  • 1 Year change+18.51%
  • Beta2.1782
Data delayed at least 15 minutes, as of Nov 08 2024 09:45 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments0.471452
Total Receivables, Net200146278
Total Inventory102115279
Prepaid expenses0.930.941.77
Other current assets, total7.6201.00
Total current assets310276612
Property, plant & equipment, net1361481,245
Goodwill, net------
Intangibles, net0.731.996.31
Long term investments4306422.78
Note receivable - long term272836
Other long term assets--044
Total assets9041,0961,959
LIABILITIES
Accounts payable154234280
Accrued expenses8.329.051.07
Notes payable/short-term debt5057110
Current portion long-term debt/capital leases2.432.4741
Other current liabilities, total152857
Total current liabilities230330489
Total long term debt3.576.02101
Total debt5665253
Deferred income tax----0
Minority interest00713
Other liabilities, total152026
Total liabilities2493561,329
SHAREHOLDERS EQUITY
Common stock262247247
Additional paid-in capital777680680
Retained earnings (accumulated deficit)(387)(191)(300)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total3.003.513.84
Total equity656740631
Total liabilities & shareholders' equity9041,0961,959
Total common shares outstanding262525
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.